Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Theravance Biopharma, Inc.TBPH · Entity 5037 | Chief Medical Officer | February 20, 2021 | February 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Theravance Biopharma, Inc.
Report date February 20, 2021 · Filed February 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 242,499 |
Reported balance
After 2021-02-20 transaction · row 1
1 source rowRow 1 · 2021-02-20 · Tax withholding · Disposed 35,672 · Balance 242,499 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aimmune Therapeutics, Inc.
Report date October 10, 2020 · Filed October 14, 2020
Section 16 reporting ended · disclosed 2020-10-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-10 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-10-10 · Other · Disposed 6,250 · Balance 0 |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-10-13 · Disposition to issuer · Disposed 13,313 · Balance 0 F1: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.11 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-13 · Disposition to issuer · Disposed 25,453 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").
F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2021 Filed Feb 23, 2021 23:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 35,672 | $18.79 | $670,276.88 |
DisclosureSEC source: 0001179110-21-002157 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,499 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 23:16 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,639 | $17.21 | $79,837.19 |
DisclosureSEC source: 0001179110-20-011367 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,171 Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 25,453 | $17.39 Strike: $17.11 | $442,627.67 |
DisclosureSEC source: 0000899243-20-028178 · doc4.xml · derivative · entry 3 HAUMANN BRETT K · CIK 0001607733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,453 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerCommon Stock, $0.0001 par value | 13,313 | $34.50 | $459,298.50 |
DisclosureSEC source: 0000899243-20-028178 · doc4.xml · nonDerivative · entry 2 HAUMANN BRETT K · CIK 0001607733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F2 · shares: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU. Read SEC document |
| October 10, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | OtherCommon Stock, $0.0001 par value | 6,250 | $34.50 | $215,625.00 |
DisclosureSEC source: 0000899243-20-028178 · doc4.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 22:21 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 25,000 | $18.29 | $457,240.00 |
DisclosureSEC source: 0001179110-20-009263 · edgar.xml · nonDerivative · entry 2 HAUMANN BRETT K · CIK 0001607733 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,810 F1 · price: This transaction was executed in multiple trades at prices from $18.22 to $18.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:21 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,646 | $18.22 | $84,650.12 |
DisclosureSEC source: 0001179110-20-009263 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,810 Read SEC document |
| May 27, 2020 Filed May 29, 2020 19:17 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 25,453 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0000899243-20-014618 · doc4.xml · derivative · entry 2 HAUMANN BRETT K · CIK 0001607733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,453 Underlying: Common Stock · 25,453 shares Expires 2030-05-26 F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 1/36th of the shares subject to the option on each monthly anniversary of the grant date, assuming continuous service as a director until each such vesting date. Read SEC document |
| May 27, 2020 Filed May 29, 2020 19:17 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantCommon Stock, $0.0001 par value | 13,313 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014618 · doc4.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,563 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest as to 1/3rd of the RSUs on each anniversary of the grant date, assuming continuous service as a director until each such vesting date. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,212 | $26.67 | $112,334.04 |
DisclosureSEC source: 0001179110-20-006524 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,456 Read SEC document |
| February 20, 2020 Filed Feb 25, 2020 00:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 33,608 | $25.90 | $870,447.20 |
DisclosureSEC source: 0001179110-20-002143 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,668 Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 23:57 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001198 · edgar.xml · nonDerivative · entry 2 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,276 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 3, 2020, the performance conditions applicable to 54,000 shares were achieved and such shares will vest on February 20, 2021, subject to the reporting person's continued service. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 23:57 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001198 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,276 Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 23:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,692 | $17.60 | $47,379.20 |
DisclosureSEC source: 0001179110-19-012013 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,276 Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 22:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,710 | $21.51 | $58,292.10 |
DisclosureSEC source: 0001179110-19-009785 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,968 Read SEC document |
| May 20, 2019 Filed May 22, 2019 22:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,705 | $19.84 | $53,667.20 |
DisclosureSEC source: 0001179110-19-006520 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,678 Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:13 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,778 | $27.00 | $210,006.00 |
DisclosureSEC source: 0001179110-19-002409 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,383 Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 22:43 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinay Shares | 47,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001558 · edgar.xml · nonDerivative · entry 2 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,161 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 5, 2019, the performance conditions applicable to 47,250 shares were achieved and such shares will vest on February 20, 2020, subject to the reporting person's continued service. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 22:43 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001558 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,911 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 22:43 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,368 | $24.79 | $182,652.72 |
DisclosureSEC source: 0001179110-18-013106 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,911 Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 23:33 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 6,683 | $26.95 | $180,106.85 |
DisclosureSEC source: 0001179110-18-010818 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,279 Read SEC document |
| May 20, 2018 Filed May 22, 2018 23:01 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 26,991 | $24.31 | $656,151.21 |
DisclosureSEC source: 0001179110-18-007371 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,962 Read SEC document |
| May 14, 2018 Filed May 16, 2018 23:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006935 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,953 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On May 14, 2018, the performance conditions applicable to 33,750 shares were achieved and such shares will vest on May 20, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:39 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,293 | $29.09 | $241,243.37 |
DisclosureSEC source: 0001179110-18-002607 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,203 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002122 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,496 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 21:37 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,846 | $28.58 | $224,238.68 |
DisclosureSEC source: 0001179110-17-014562 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,496 Read SEC document |
| August 20, 2017 Filed Aug 22, 2017 22:28 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,064 | $27.40 | $193,553.60 |
DisclosureSEC source: 0001179110-17-011747 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,342 Read SEC document |
| May 20, 2017 Filed May 23, 2017 23:59 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,065 | $36.83 | $260,203.95 |
DisclosureSEC source: 0001179110-17-007877 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,406 Read SEC document |
| March 07, 2017 Filed Mar 8, 2017 23:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 424 | $30.80 | $13,059.20 |
DisclosureSEC source: 0001179110-17-004273 · edgar.xml · nonDerivative · entry 2 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,471 Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 23:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 13,576 | $31.52 | $427,915.52 |
DisclosureSEC source: 0001179110-17-004273 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,895 F1 · price: This transaction was executed in multiple trades at prices from $31.18 to $32.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 20, 2017 Filed Feb 23, 2017 00:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 14,434 | $33.78 | $487,580.52 |
DisclosureSEC source: 0001179110-17-002989 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,471 Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001998 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,905 Read SEC document |
| November 20, 2016 Filed Nov 22, 2016 23:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,388 | $31.96 | $172,200.48 |
DisclosureSEC source: 0001179110-16-031976 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,905 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.